Clinically Isolated Syndrome clinical trials at UCSF

3 research studies open to eligible people

Clinically Isolated Syndrome is a first episode of neurological symptoms. UCSF is working on clinical trials that study the effects of ocrelizumab on patients with CIS and MS. One trial looks at how ocrelizumab might transfer through the placenta during pregnancy. Another trial examines the amount of ocrelizumab that enters breastmilk during lactation. Finally, a third trial investigates ocrelizumab's effects on the cerebrospinal fluid biomarkers of newly diagnosed MS and high risk CIS patients.

Showing trials for

  • A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab

    open to eligible females ages 18-40

    This study will evaluate the pharmacokinetics of ocrelizumab in the breastmilk of lactating women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] treated with ocrelizumab, by assessing the concentration of ocrelizumab in mature breastmilk, as well as the corresponding exposure and pharmacodynamic effects (blood B cell levels) in the infants.

    San Francisco, California and other locations

  • A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy

    open to eligible females ages 18-40

    This study will evaluate the potential placental transfer of ocrelizumab in women with clinically isolated syndrome (CIS) or multiple sclerosis (MS) [in line with the locally approved indications] whose last dose of ocrelizumab was administered any time from 6 months before the last menstrual period (LMP) through to the first trimester (up to gestational week 13) of pregnancy, and the corresponding pharmacodynamic effects (B cell levels) in the infant.

    San Francisco, California and other locations

  • Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

    open to eligible people ages 18-50

    Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic inflammation.

    San Francisco, California

Our lead scientists for Clinically Isolated Syndrome research studies include .

Last updated: